Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

Core Insights - Kymera Therapeutics is advancing a new class of oral small molecule degrader medicines for immunological diseases, with data from its KT-621 BroADen Phase 1b clinical trial set to be presented at the AAD 2026 Annual Meeting [1][2] Group 1: Clinical Trial Information - The KT-621 BroADen Phase 1b clinical trial focuses on patients with atopic dermatitis and will be presented in a late-breaking oral session on March 28, 2026 [1][7] - KT-621 is a first-in-class, once-daily oral degrader of STAT6, targeting IL-4/IL-13 signaling, which is central to Type 2 inflammation [4] Group 2: Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation (TPD) to develop innovative medicines for critical health issues [5] - The company aims to build a leading pipeline of oral small molecule degraders to provide effective therapies for patients with immunological diseases [5]